US Stock MarketDetailed Quotes
ETNB 89bio
- 7.990
- +0.050+0.63%
Close Dec 23 16:00 ET
- 8.150
- +0.160+2.00%
Post 17:50 ET
939.48MMarket Cap-2.70P/E (TTM)
8.100High7.750Low1.21MVolume7.910Open7.940Pre Close9.61MTurnover1.50%Turnover RatioLossP/E (Static)117.58MShares16.63052wk High2.48P/B642.40MFloat Cap6.43052wk Low--Dividend TTM80.40MShs Float47.253Historical High--Div YieldTTM4.41%Amplitude2.000Historical Low7.947Avg Price1Lot Size
About 89bio Company
89bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. Its product pipeline includes pegozafermin, FGF21, NASH, and SHTG. The company was founded on January 18, 2018 and is headquartered in San Francisco, CA.
Company Profile
SymbolETNB
Company Name89bio
Listing DateNov 11, 2019
Issue Price16.00
Founded2018
CEOMr. Rohan Palekar
MarketNASDAQ
Employees70
Fiscal Year Ends12-31
Address142 Sansome Street,2nd floor
CitySan Francisco
ProvinceCalifornia
CountryUnited States of America
Zip Code94104
Phone1-415-432-9270
Websitehttp://www.89bio.com
Company Executives
- Name
- Position
- Salary
- Rohan Palekar
- Chief Executive Officer and Director
- 5.59M
- Francis W. Sarena
- Chief Operating Officer
- --
- Quoc Le-Nguyen
- Chief Technical Operations Officer and Head of Quality
- 2.51M
- Dr. Hank Mansbach, M.D.
- Chief Medical Officer
- 2.54M
- Ryan Martins
- Chief Financial Officer and Principal Accounting Officer
- --
- Dr. Steven M. Altschuler, M.D.
- Chairman of the Board
- 385.83K
- Dr. Charles A. McWherter, PhD.
- Director
- --
- Martin Babler
- Director
- --
- Dr. Edward Morrow Atkinson, III
- Independent Director
- 354.60K
- Dr. Michael Hayden
- Independent Director
- 358.33K
- Lota S. Zoth, C.P.A.
- Independent Director
- 363.33K
- Dr. Derek DiRocco, PhD
- Independent Director
- 352.33K
- Kathleen D. Laporte
- Independent Director
- 360.17K
Heat List
US
Overall
Symbol
Price
% Chg
No Data
